Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

(2021) Monika L. Metzger et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

(2021) David J Straus et al.   Lancet Haematology

Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study

(2018) Paolo Strati et al.   HAEMATOLOGICA

Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort

(2018) Todd M Gibson et al.   LANCET ONCOLOGY

Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study

(2018) Franco Locatelli et al.   Lancet Haematology

Radiation-Related New Primary Solid Cancers in the Childhood Cancer Survivor Study: Comparative Radiation Dose Response and Modification of Treatment Effects

(2016) Peter D. Inskip et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study

(2016) Sogol Mostoufi-Moab et al.   JOURNAL OF CLINICAL ONCOLOGY

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

(2015) Michael Schaapveld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials

(2013) Michael Zach Koontz et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

(2013) Anas Younes et al.   LANCET ONCOLOGY

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

(2012) A. Younes et al.   BLOOD

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

(2012) Y. L. Kasamon et al.   BLOOD

Breast Cancer Risk After Supradiaphragmatic Radiotherapy for Hodgkin's Lymphoma in England and Wales: A National Cohort Study

(2012) Anthony J. Swerdlow et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin

(2012) Anas Younes et al.   NATURE REVIEWS DRUG DISCOVERY

Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study

(2010) S. M. Castellino et al.   BLOOD

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Effects of Radiation Exposure among Adult Survivors of Childhood Cancer: Results from the Childhood Cancer Survivor Study

(2010) Gregory T. Armstrong et al.   RADIATION RESEARCH

Clonotypic B cells in classic Hodgkin lymphoma

(2009) R. Kuppers   BLOOD

Circulating clonotypic B cells in classic Hodgkin lymphoma

(2009) R. J. Jones et al.   BLOOD